Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;59 Suppl 1(Suppl 1):S55-60.
doi: 10.1093/cid/ciu266.

Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence

Affiliations

Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence

K Rivet Amico et al. Clin Infect Dis. 2014 Jul.

Abstract

Despite considerable discussion and debate about adherence to preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV), scant data are available that characterize patterns of adherence to open-label PrEP. The current evidence base is instead dominated by research on adherence to placebo-controlled investigational drug by way of drug detection in active-arm participants of large randomized controlled trials (RCTs). Important differences between the context of blinded RCTs and open-label use suggest caution when generalizing from study product adherence to real-world PrEP use. Evidence specific to open-label PrEP adherence is presently sparse but will expand rapidly over the next few years as roll-out, demonstration projects, and more rigorous research collect and present findings. The current evidence bases established cannot yet predict uptake, adherence, or persistence with open-label effective PrEP. Emerging evidence suggests that some cohorts could execute better adherence in open-label use vs placebo-controlled research. Uptake of PrEP is presently slow in the United States; whether this changes as grassroots and community efforts increase awareness of PrEP as an effective HIV prevention option remains to be determined. As recommended by multiple guidelines for PrEP use, all current demonstration projects offer PrEP education and/or counseling. PrEP support approaches generally fall into community-based, technology, monitoring, and integrated sexual health promotion approaches. Developing and implementing research that moves beyond simple correlates of either study product use or open-label PrEP adherence toward more comprehensive models of sociobehavioral and socioecological adherence determinants would greatly accelerate progress. Intervention research is needed to identify effective models of support for open-label PrEP adherence.

Keywords: PrEP adherence; behavioral science; social science; study product adherence.

PubMed Disclaimer

References

    1. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS. 2012;7:542–8. - PubMed
    1. Baeten J, Celum C. Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS. 2012;7:514–9. - PMC - PubMed
    1. Celum CL. HIV preexposure prophylaxis: new data and potential use. Top Antivir Med. 2011;19:181–5. - PMC - PubMed
    1. Baeten JM, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep. 2013;10:142–51. - PMC - PubMed
    1. Mayer K, Gazzard B, Zuniga JM, et al. Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. J Int Assoc Provid AIDS Care. 2013;12:208–16. - PubMed

Substances